Bactiguard Holding AB (Bactiguard)(STO:BACTIB), a Swedish medical device company, reported on Tuesday net loss of SEK0.5m, or SEK0.02 per share, for the third quarter of 2018, from July 2018 to September 2018.
This was a decline over net loss of SEK 0.4m, or SEK0.01 per share, in Q3 2017.
Revenues for the quarter amounted to SEK35.7m, up by 3% as compared with SEK34.8m in Q3 2017.
BIP (Bactiguard Infection Protection) sales for the quarter amounted to SEK3.9m, down by 24% as compared with SEK5.2m in Q3 2017, which is explained by the fact that this quarter did not contain any deliveries to China, as compared with Q3 2017.
Bactiguard develops and supplies infection protection solutions, which reduce the risk of healthcare associated infections and the use of antibiotics.
(EUR1.00=SEK10.33)
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project